{
  "docId": "019de076-4eee-72eb-9f75-bef42550a1c1",
  "docSlug": "3c2d586ebe2940705b3e5004470d76e3",
  "documentTitle": "Kymera | Investor Presentation Deck | 41 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 41,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a split-layout to contrast technical mechanism/data (left) with strategic market opportunity (right).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4eee-72eb-9f75-bef42550a1c1/39",
  "deckHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1",
  "deckJsonHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1.json",
  "deckAnchorHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "callout",
      "text": "First-in-class Opportunity to Address p53 WT Tumors Across a Variety of Tumor Types",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b2ea5ec-7308-41c0-9705-dafd617f802f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.45,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "KT-253, unlike SMIs, overcomes the feedback loop which up-regulates MDM2 production and in doing so more effectively stabilizes the tumor suppressor p53. KT-253 inhibits tumor cell growth with picomolar activity and is more than 200-fold more potent than clinically active MDM2 SMIs, enabling intermittent dosing to improve therapeutic index. Interim Phase 1a data from Arm A show evidence of target engagement and p53 pathway activation and initial signs of antitumor activity without DLTs including typical hematological toxicity. Arm B (high grade myeloid malignancies including AML) enrollment initiated. Additional clinical and preclinical data supporting biomarker-based patient selection strategy to be disclosed in 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f94692c-aa17-459a-be4b-dbbbfbac9a59",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.55,
        "y": 0.4
      },
      "kind": "list",
      "text": "First degrader against a clinically proven but inadequately drugged target, MDM2. Profound single agent activity in preclinical liquid and solid tumor models and initial evidence of antitumor activity in patients in Phase 1a. Clinical development strategy includes accelerated registration path in p53 WT tumors with high sensitivity to degrader mechanism such as AML, lymphomas and solid tumors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46ee6aac-27d8-44aa-a3ab-7f7c9c035a7f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "KT-253: Emerging Clinical Data Support Therapeutic Hypothesis for MDM2 Degrader",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9502e6e5-f646-4db6-b22a-26c86ca0484e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Call to action",
      "slug": "call-to-action",
      "agent": null,
      "layer": "slide",
      "matchId": "63851980-c9b2-4658-8096-fd15ecc29c08",
      "evidence": "callout/primary: First-in-class Opportunity to Address p53 WT Tumors Across a Variety of Tumor Types",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}